CD274 and pancreatic neoplasm: In fact, there are ongoing clinical trials for NSCLC, breast cancer, metastatic pancreatic adenocarcinoma, advanced melanoma, pancreatic cancer, and metastatic renal-cell carcinoma with a combination of PD-L1 and autophagy inhibitors.